2021 League Tables

As requested by some of y'all on this forum, here are the 2021 league tables, courtesy of Factset.

Global
Global 2021 League Tables
Global League Tables - Sell-side Advisors
Global Sell-side 2021
Global League Tables - Buy-side Advisors
Global Buy-Side 2021
United States
2021 US League Table
 United States League Tables - Sell-side Advisors
US Sell-Side 2021
 United States League Tables - Buy-side Advisors
US Buy-Side 2021
Global ECM
Global ECM 2021

Comments (152)

  • Intern in IB-M&A
Jan 8, 2022 - 6:56pm

Thanks for posting! Interesting to see Rothschild's disparity between their global and US presence. Basically tied with JEF globally but not even in the top 20 in the US. Always heard their global and domestic reputations differed but didn't realize how just how big the difference is.

  • Intern in HF - Event
Jan 9, 2022 - 3:40am

Confused about this cuz looking at Rothschild US YTD November 2021 they were ranked 22nd. Tf happened?Source: https://www.factset.com/hubfs/mergerstat_em/monthly/US-Flashwire-Monthly.pdf

  • Intern in IB - Gen
Jan 8, 2022 - 7:02pm

Centerview being 9 despite their small size is just crazy to me

Jan 10, 2022 - 1:05pm
WS_Jerry, what's your opinion? Comment below:

Yeah explains how they can afford those incredible pays

I think I did this right

  • Teller in VC
Jan 9, 2022 - 10:23am

Is this the underlying data? KKR/Telecom Italia hasn't transacted to my knowledge

  • Associate 1 in HF - Other
Feb 15, 2022 - 8:22am

Hmmm Australia witnessed a few large transactions last year. Tad surprising for a small market. 

Jan 10, 2022 - 1:02pm
markiv199, what's your opinion? Comment below:

Yep, and buysides are basically a joke. Sell sides are where you learn the most

Array
  • 1
  • 7
  • Analyst 1 in IB-M&A
Jan 8, 2022 - 7:32pm

How are some shops good at buyside advising and others good at sellsides? for instance, how is BarCap beating a lot of strong shops including MS as a US buyside advisor but getting drilled in US sell-sides?

  • Associate 1 in IB-M&A
Jan 8, 2022 - 7:35pm

A lot of Balance-sheet banks (JPM, RBC, BMO, Barclays, DB, UBS) are much higher on the league tables for buy-side advisory because they get provide the financing for the transactions and also get advisory credit as well. Often what happens on larger buy-side transactions is that a lot of BBs are brought on for financing and all get advisory credit while a single BB or EB does most of the actual advisory.

  • Analyst 2 in PE - LBOs
Jan 8, 2022 - 7:45pm

Yeah it's pretty deceiving but to be fair it can be the case that there won't be 'that' many banks either.Additionally, it's not like all the banks will get advisory credit. It can be like the bank that does the most will get it. And they dont 'do nothing' either. There's still a lot of BS involved, it's just that there's a lot less because the buy-side people have their own team and aren't going to pay what some bank recommends for an asset.Flip side, a sell side advisor has some genuine value add in that aspect.Overall though the boutiques get the credit they do for a reason (independent advisors) and the BB's have a bloated importance.(worked at BarCap).

  • Intern in IB-M&A
Jan 13, 2022 - 7:18pm

Incoming Barclays analyst who did my SA at a top MM's M&A group...how does that translate into the analyst experience in a coverage group? Did I make a wrong decision in giving up solid M&A experience for prestige?

  • Anonymous Monkey's picture
  • Anonymous Monkey
  • Rank: Chimp
Jan 14, 2022 - 4:16pm
Anonymous Monkey, what's your opinion? Comment below:

Sellsides typically depend on board relationships or something historical (dual track IPO, lending, personal) so are harder to land but more profitable. Buysides is a gamble because you're gabling that you're picking the best horse. Commercial banks can also get in by bankrolling the financing package

Run the league tables by wallet and it will be clearer

  • Intern in IB-M&A
Jan 8, 2022 - 7:50pm

del

  • Analyst 1 in IB-M&A
Jan 9, 2022 - 9:18pm

Question for Industrials USA league table, Citi/BAML/BarCap basically have around the same amount of transaction value, does anyone (maybe working there) see any further consolidation in the league tables as to which bank may win more deals into the future? Seems like at the moment they all 3 have super solid shops (considering the hype behind Citi/BarCap Industrials, unsure about BAML).

Controversial
  • Junior Trader in PropTrad
Jan 8, 2022 - 10:01pm

Deutsche is not a BB anymore lol

  • Principal in PE - LBOs
Jan 9, 2022 - 2:16pm

Facts, they're moving away from a focus on investment banking

  • Intern in IB-M&A
Jan 8, 2022 - 10:27pm

This is very marginal, but can anyone comment on the disparity between BofA and Citi? Is Citi that bit stronger than BofA or are league tables not indicative of overall platform strength 

  • Associate 1 in IB-M&A
Jan 8, 2022 - 10:46pm

Highly dependent on group, product, and geography, but personally I consider Citi and BofA pretty interchangeable and comparable, with BofA perhaps slightly stronger in the US and Citi stronger in LatAm and Asia

  • Intern in IB - Gen
Jan 8, 2022 - 10:55pm

RX league table?

  • Intern in IB - Gen
Jan 11, 2022 - 1:27pm

right right that's interesting - by that logic, I would imagine any RX league table would be top-skewed (i.e. only accounts for the announced / public RX deals)


but wouldn't you run into the same issue regarding lack of public disclosure of private deals for M&A league tables as well? or do you think it's proportionally more hush-hush for RX deals given your point (1) [information asymmetry sometimes beneficial given that suppliers could get flustered]

  • Prospect in IB - Cov
Jan 8, 2022 - 11:49pm

Is it possible to stratify the top deals by coverage?

  • Analyst 1 in IB - Cov
Jan 9, 2022 - 12:29am

FIG league table?

  • Prospect in PE - LBOs
Jan 9, 2022 - 12:46am

Sorry if dumb question but how is Moelis so low but regarded as one of the best banks? Thank you!

  • Associate 1 in IB-M&A
Jan 9, 2022 - 12:58am

EBs typically can shift quite a bit from year to year anywhere from ~10th to 30th in league tables depending on if they can land a few landmark deals that shoot them way up in league tables (ex. in 2019 Moelis was 14th in league tables with the Celgene/Bristol Myers Squibb adding $93B to their deal volume and PWP was 29th while it was basically flipped this year with PWP landing the $59B Warner Media/Discovery deal). Also, Moelis has a lot more transactions with undisclosed values compared to other EBs as they do far more sponsor deals than most other EBs, and league tables obviously don't take that into account.

Also, for what it's worth, most of the EBs have similar reputations to clients and across the street, and the difference in reputations comes from the junior level in terms of PE exits, which Moelis historically does very well in as their analysts get a super rigorous experience (generalist M&A/RX model, very lean + high deal volume = analysts get their reps in, firm and MDs have great relationships with sponsors which also helps out placement).

Jan 9, 2022 - 6:11pm
IB_analyst24, what's your opinion? Comment below:

Moelis has changed from a generalist to a sector focused model. How do you think this will affect the recruiting for the coming analyst class?

  • Analyst 1 in IB - Restr
Jan 9, 2022 - 12:47am

Curious to hear about anyone's thoughts on JEF. Was this expected?

Most Helpful
  • Analyst 2 in IB - Gen
Jan 9, 2022 - 1:26am

JEF has basically been continuing its trend, which is a good thing considering it's been the fastest growing bank on Wall Street for some time. JEF has been able to capitalize on building sponsor relationships through its LevFin practice over the past few years. Now that the sponsors that JEF helped finance are selling their Portcos, JEF is able to get a piece of that sell-side advisory. JEF has also been building its LevFin practice through its partnerships with Mass Mutual and SMBC.

JEF has also been very focused on poaching MDs (something like a fifth of MDs at JEF have been there for less than a year) across all industries, and they're a much stronger bank all-around compared to just a few years ago. They've also been focusing on expanding their HC practice through building relationships through their ECM practice (HC ECM 2021 League Tables shown below).

2021 Healthcare ECM

That being said, JEF also has some growing pains. I don't work at JEF, but I've heard some things from people I know at JEF that through their aggressive poaching strategy, they've picked up some a lot of great MDs but also quite some dead weight with very expensive guaranteed comp packages.

  • Analyst 1 in IB - Restr
Jan 9, 2022 - 1:51am

Thank you, super informative! How do you see them competing with BB/EBs in the next 5/10 years? Taking more market share? Which groups do you see the most growth, tech and HC?

  • Analyst 1 in IB - Gen
Jan 9, 2022 - 2:21am

JEF #1 in US LBO financing this year. LevFin business is the definition of tier 1 in the US along with BAML and CS.

  • Intern in IB-M&A
Jan 9, 2022 - 6:17pm

Sat in on a call with the head IB (Chris Kanoff) and it was great to hear his perspective on recruiting constantly for MDs, asp mind you this was during COVID where there's recruiting pitches for MDs took place primarily over zoom. Also I wld add further emphasis on the SMBC deal w/ their LevFin arm these relations will help them with advisory especially in the buyside w/ financing deals.

Jan 9, 2022 - 1:53am
PatrickBateman1, what's your opinion? Comment below:

A lot for Interns to talk about lmfao

Array
  • 1
  • Analyst 2 in IB - DCM
Jan 9, 2022 - 3:33am

Canada tables?

Jan 12, 2022 - 5:14am
rubians, what's your opinion? Comment below:

https://www.lma.eu.com/application/files/4016/2755/1995/Dealogic_Quarterly_Rankings_LevFin_H1_2021.pdf

  • Intern in IB - Gen
Jan 9, 2022 - 10:05am

Would anyone happen to have the healthcare league tables by U.S sell-side/buy-side? Thanks!

  • Analyst 2 in IB-M&A
Jan 9, 2022 - 11:32am

What's the consensus on Liontree? A few years ago they were invisible, but now they're landing several huge mandates and on the league tables they're above PWP and PJT, despite having significantly less headcount. Are they officially an EB now, albeit TMT specialist?

  • Analyst 2 in IB - Gen
Jan 9, 2022 - 11:52am

They really weren't really invisible and definitely didn't just emerge out of nowhere (pulled up 2015 league tables and they were 15th). There's no such thing as "officially an EB" (no actual professional uses that term and there's really no defined criteria), and they've always had the reputation as a top TMT bank.

  • Associate 1 in PE - Growth
Jan 9, 2022 - 11:36am

Just as a disclaimer reading these:

The dataset is only getting pulled off publicly announced transactions. As a result, any player that does deals sub $2B likely is getting undercounted massively because the deals might not get disclosed. Would guess BB's like Goldman that have a strong mm presence and obviously mm players or EB's that dabble in the UMM space aren't being accurately represented. Fun to look at though.

  • Analyst 2 in IB - Gen
Jan 9, 2022 - 11:46am

That's fair, looking at Factset with deal count by transactions with disclosed values vs all transactions, it appears that banks that are underrepresented in league tables are Lazard, Rothschild, Jefferies, Guggenheim, Moelis, and HL, which all happen to also be banks that do a lot of sponsor deals. The BBs' places on the tables seem pretty representative by the % of deals with disclosed values.

  • Intern in IB - Gen
Jan 14, 2022 - 2:18pm

Why aren't MM deals as commonly disclosed?

  • Intern in IB-M&A
Jan 9, 2022 - 12:14pm

Anyone got some older league tables by any chance? Would be interesting to see how everything has changed over time.

  • Analyst 2 in IB - Gen
Jan 9, 2022 - 12:30pm

Why does the 2008 league tables includes both Wachovia and WF under WF and both BofA and ML under BofA but not Lehman and Barclays under Barclays? It's interesting to see how consistent things have been over the years, with the only obvious moves being Greenhill falling off from being among the best boutiques and Jefferies rising out of nowhere.

Jan 9, 2022 - 12:18pm
Calabi-Yau, what's your opinion? Comment below:

Interesting to see MS at #5 of US buy sides given they focus a lot on these vs sellsides..

Laborare Pugnare Parati Sumus

Jan 9, 2022 - 1:02pm
maplesyrup334, what's your opinion? Comment below:

Damn Goldman is leagues ahead of everyone else. I can't imagine they advise better than BAML or Citi. Is it just perceived reputation / existing relationships that make them #1 all the time.  

Jan 10, 2022 - 1:49pm
Infra M+A, what's your opinion? Comment below:

League tables sorted by transaction value is really more a prestige of deals ranking. Doesn't necessarily make them any better or worse than others, just means they had some of the bigger ticket deals. League tables sorted by deal volume gives an impression of how much work they are winning, how successful they are in the market, how busy and how much experience the junior staff gets. If you could ever do league tables based on deal fees, that certainly would be speak to overall success. Bigger transaction value doesn't 100% equate to bigger fees / higher profit. A larger ticket size usually means a lower success fee % (which can still mean more in absolute dollars). And deal fees per number of deals or deal fees per headcount would really even the playing field and give a perspective of based on the size of the shop, how successful are they really.

But regardless of all that, league tables based on transaction value is still the most basic view of ranking how successful each shop has been during the year, and they're still fun rankings to see.

  • Analyst 1 in IB - Gen
Jan 9, 2022 - 5:42pm

2021 US LBO per BBG

1. Jefferies 12,996 deal value, 115 transactions, 5.63% share 

2. barclays 12,495 deal value, 117 transactions, 5.41% share

3. BofA 12,412 deal value, 109 transactions, 5.37% share

4. CS 12,397 deal value, 134 transactions, 5.37% share

5. DB 11,363 deal value, 100 transactions, 4.92% share

6.  Antares 10,980 deal value, 94 transactions, 4.75% share

7. BMO 10,257 deal value, 115 transactions, 4.44% share 

8. GS 10,006 deal value, 113 transactions, 4.33% share 

9. RBC 9,683 deal value, 98 transactions, 4.19% share

10. UBS 8,334 deal value, 82 transactions, 3.61% share

11. JPM 7,298 deal value, 69 transactions, 3.16% share 

biggest takeaways here is obviously jefferies dominance in the sponsor space without a balance sheet. Barclays in at 2 is also a bit of a surprise. JPM not even in the top 10 is also an eye opener and really shows how corporate driven and risk averse their levfin franchise is. 

  • Associate 1 in IB-M&A
Jan 9, 2022 - 5:58pm

- Smaller than most comparable larger full-service banks yet still holds its place in league tables.

- Does a lot of risky below-investment-grade lending

- Has an... interesting CEO for lack of a better word

Is Jefferies the new Lehman?

  • Intern in IB-M&A
Jan 9, 2022 - 6:24pm

What happened with UBS? I thought historically they were among the top for sponsor-backed LBO financings?

  • Associate 3 in IB - Gen
Jan 9, 2022 - 6:30pm

Bloomberg league tables are a little distorted. It's only LBO loans (ex HY) and they also include revolvers and ABLs that are part of LBO cap structures which kind of gives a slight edge to the balance sheet banks. 

Jan 9, 2022 - 9:05pm
reformed, what's your opinion? Comment below:

The ROE on these loans is terrible for the large banks, and they only do them to the extent they have to in order to support the broader relationship. Goal from the big banks is to minimize the dollar value of loans given while still maximizing the fees generated by the bank overall.

It's a huge win if the bank is able to maintain their place on the M&A league tables while lending less than peers.

Array
  • 1
Jan 10, 2022 - 10:02am
ThiccPik, what's your opinion? Comment below:

League tables really only make sense for Bulge brackets and even then, not really outside of cap markets (and even THEN, we still have private raises). There are so so many undisclosed deals and work done that league tables are the epitome of trying to force rank players by comparing Apples to Oranges.

An example:  look at the huge split ups which have occurred and are occurring (Toshiba, GE, etc.) . That is a "$0" deal by league table metrics but clearly the advisors on it will earn massive undisclosed fees. 

I'm not saying they have zero value to get a sense but the college-aged contingent on this site is viewing them the same way they look at (also flawed) college rankings, as an absolute arbiter of who is "better", and it's not how the world actually works. 

Array

  • 5
Jan 10, 2022 - 1:40pm
Infra M+A, what's your opinion? Comment below:

I always find it interesting how, for example, if you were to sort by deal volume a shop like PwC at 809 transactions is first place and miles ahead of the other shops, but in terms of deal value they're like 10% of what the top IBs have done. When looking at learning and growth opportunities for employment, does that point to a consideration of quantity vs quality and what would give the better learning experience?

  • Analyst 1 in IB - Gen
Jan 10, 2022 - 1:46pm

Does anyone have league tables for energy / O&G?

  • Intern in IB - Cov
Jan 10, 2022 - 4:26pm

Also interested 

  • Prospect in IB-M&A
Jan 12, 2022 - 4:17pm

They have been doing really well recently and growing in the Americas

Jan 12, 2022 - 4:02pm
Ion26, what's your opinion? Comment below:

Does Jefferies reporting poor Q4 revenue/earnings, even though IB division outperformed matter? Like in terms of people's bonuses and such. Stock is down 10% today

  • Prospect in IB - Gen
Jan 12, 2022 - 7:04pm

Can anyone speak on DB? Seems like every time it is brought up there is only negativity. Is it that bad? Anyone have any insight on culture etc.

  • Prospect in IB - Gen
Jan 13, 2022 - 12:54pm

Why is MS considered to be a "better" IB than JPM when JPM is always above them in the league tables? Genuinely curious because it seems that prospects would take a MS offer over a JPM one 100% of the time. Could be wrong though.  

  • VP in IB - Gen
Jan 14, 2022 - 3:56pm

Because MS is generally hired for their advice and not due to lending, which is a big factor in JPM's dealflow. Deal volume and fee dollars per banker at MS are also much higher given a smaller team vs. JPM, who are probably the largest IB in the world. M&A has always been the crown jewel in of MS' IB division.

Not shitting on JPM at all though, they're a fantastic bank.

  • Incoming Analyst in IB-M&A
Jan 16, 2022 - 4:24pm

Why are DB, UBS, and RBC always shit on? Judging by the league tables they do pretty solid, especially on a value per deal basis

  • Analyst 2 in IB-M&A
Jan 16, 2022 - 6:01pm

Because DB and RBC are balance sheet banks that get boosted on the league table through getting buy-side advisory credit for providing deal financing. Just look at the discrepancy between where they are on the global sell-side vs buy-side league tables. If you get a chance to sort through FY-21 earnings reports once they all release, you can see the "real" difference between the M&A strength of banks by looking at the amount of their IB revenue that's from advisory for the banks that do break it down.

As for UBS, they have a pretty strong M&A franchise led by their sponsors relationships (much like CS and JEF), but they get shit on because they've taken a hard fall since the GFC and every time it looks like they've started to rebuild, their top bankers get poached again. Case in point, look at SVB and UBS Tech this year. Just when UBS Tech was finishing their rebuild from falling apart in 15/16, they get poached again.

  • Associate 2 in IB-M&A
Jan 16, 2022 - 5:39pm

https://www.fnlondon.com/articles/citigroup-hires-jpmorgan-dealmaker-truesdale-for-technology-banking-push-20210908

https://www.globalcapital.com/asia/article/291vhz4m4kne0j1qnqs5c/people-and-markets/people-news/citi-poaches-top-goldman-banker

https://money.usnews.com/investing/news/articles/2021-08-17/citigroup-poaches-shah-from-credit-suisse-to-boost-tech-m-a

https://www.efinancialcareers.com/news/2021/02/patrick-leonard-fintech-barclays-citi

  • Associate 1 in IB-M&A
Jan 16, 2022 - 6:17pm

Libero sapiente dolor non provident inventore non eos. Hic minima et ut porro et consequatur. Quia quisquam repudiandae animi ab unde dolor. Voluptatem neque ipsam recusandae soluta delectus rerum.

Eos mollitia eos aut. Rerum dolorem vel qui impedit ut. Officia consequatur eius qui qui voluptas.

Qui voluptates non dolores dolore reiciendis voluptatem. Minus id incidunt omnis pariatur aliquid. Expedita qui quisquam fuga.

Jan 16, 2022 - 11:35pm
AttackSnail, what's your opinion? Comment below:

Molestias itaque quisquam corporis consequatur. Soluta sit nobis odit qui quia. Perferendis itaque nihil officia hic et repellat reprehenderit molestiae. Assumenda error laudantium voluptatem esse ut tenetur quidem. Sit quod et optio qui. Non et sunt quia consequuntur ut laudantium nulla. Ut quo nihil aspernatur.

Odio repellendus est quibusdam et rerum omnis ipsam incidunt. Et mollitia perspiciatis qui minus. Delectus veniam velit voluptatem autem omnis iusto.

  • Analyst 2 in IB-M&A
Jan 17, 2022 - 12:10pm

Incidunt placeat consectetur animi sapiente ipsa et. Harum deleniti unde asperiores quis nemo. Nulla est voluptatibus nesciunt magnam. Placeat eos et molestiae quia vel aut. Fugiat aut dolorem soluta maxime fugit sint sed.

Autem nobis voluptas asperiores rerum. In dicta optio optio quo blanditiis. Et recusandae voluptatem placeat temporibus. Iure accusamus dolores ducimus quia quis ea temporibus delectus.

Jan 17, 2022 - 1:06pm
AttackSnail, what's your opinion? Comment below:

Qui aut laudantium dolor consequatur ipsa dolorem. Accusantium expedita voluptatem reiciendis architecto laboriosam et. Pariatur et in quia omnis unde quia exercitationem. Reprehenderit non modi aperiam iure sit. Expedita dicta est ut et.

Quo totam illum dolor ducimus aut at corporis. Vel ut fuga maxime magni ad. Est voluptatem dolorem quae consequatur perspiciatis nam. Et est veritatis laborum ad unde aspernatur perspiciatis consequuntur.

  • Prospect in IB-M&A
May 9, 2022 - 5:53pm

Error alias necessitatibus voluptatibus et dolor omnis natus. Quam ut commodi illum a numquam voluptatem et explicabo. Dolore cum laudantium dolore omnis asperiores sit mollitia. Omnis in rerum ratione accusantium. Sed vero asperiores enim voluptas aliquid et.

Eveniet nemo id est ea est. Consectetur fuga perferendis nihil eos et voluptatem repudiandae.

Aut sequi tempora quia nihil. Perferendis vitae alias maiores et qui. Itaque est fugiat distinctio vel perspiciatis distinctio explicabo.

Start Discussion

Career Advancement Opportunities

September 2022 Investment Banking

  • Jefferies & Company (▲05) 99.6%
  • Lincoln International (= =) 99.2%
  • Bank of America Merrill Lynch (▲04) 98.8%
  • Financial Technology Partners (+ +) 98.5%
  • Evercore (▽02) 98.1%

Overall Employee Satisfaction

September 2022 Investment Banking

  • Jefferies & Company (▲12) 99.6%
  • Greenhill (▲07) 99.2%
  • Evercore (▲01) 98.8%
  • PJT Partners (▽02) 98.4%
  • Macquarie Group Limited ABN (▲21) 98.1%

Professional Growth Opportunities

September 2022 Investment Banking

  • Jefferies & Company (▲05) 99.6%
  • Lincoln International (▲03) 99.2%
  • PwC Corporate Finance (▲12) 98.8%
  • Bank of America Merrill Lynch (▲05) 98.5%
  • Houlihan Lokey (▲05) 98.1%

Total Avg Compensation

September 2022 Investment Banking

  • Director/MD (10) $613
  • Intern/Summer Analyst (318) $407
  • Vice President (38) $392
  • Associates (209) $257
  • 2nd Year Analyst (130) $163
  • 3rd+ Year Analyst (19) $160
  • 1st Year Analyst (438) $151
  • Intern/Summer Associate (83) $150